催产素治疗单纯性肥胖的疗效与安全性研究

Efficacy and safety of oxytocin for treatment of simple obesity

目的探讨催产素(OXT)鼻内给药治疗单纯性肥胖患者的疗效与安全性。方法采用随机、双盲、安慰剂对照的方法将符合研究要求的30例单纯性肥胖患者分为治疗组和安慰剂组,分别接受催产素鼻喷剂和安慰剂(生理盐水)鼻喷剂,治疗12周。观察两组治疗前后的体重、体重指数(BMI)、腰围、臀围、血脂及肝肾功能变化情况,评价其临床疗效和安全性。用酶联免疫法(ELISA)检测两组治疗前0周和治疗后12周血清C反应蛋白(CRP)和脂联素(APN)水平。结果治疗后12周,治疗组体重、BMI、腰围、臀围下降幅度与安慰剂组比较,差异有统计学意义(P<0.05),治疗组大于安慰剂组。治疗组治疗后12周TC、TG、LDL-C与治疗前比较,差异有统计学意义(P<0.05),均有所下降,而HDL-C在治疗前后差异无统计学意义(P>0.05)。治疗后12周,治疗组TC、TG、LDL-C与安慰剂组比较,差异有统计学意义(P<0.05),治疗组低于安慰剂组。治疗后12周,治疗组ALT与治疗前比较,差异有统计学意义(P<0.05),治疗后12周较治疗前下降。治疗组AST、Scr、BUN治疗前后差异无统计学意义(P>0.05)。与治疗前比较,治疗后12周治疗组CRP下降,APN升高(P<0.05)。与安慰剂组比较,治疗后12周治疗组CRP下降,APN升高(P<0.05)。结论催产素可以减轻单纯性肥胖患者体重,还能改善血脂紊乱,改善肥胖慢性炎症状态,未发现有肝肾功能的损害。

Objective To evaluate the efficacy and safety of oxytocin nasal spray in treating simple obesity.Methods Thirty cases of simple obesity were divided into two groups by a randomized,double-blind,placebocontrolled trial.The treatment group had 15 cases treated with oxytocin nasal spray,the placebo-control group had 15 cases treated with placebo(saline)nasal spray for a continuous 12-week period.The changes of body weight,body mass index(BMI),waist circumference,hip circumference,blood lipids,and liver and kidney functions were observed before and after treatment.Enzyme-linked immunosorbent assay(ELISA)was used to detect serum adiponectin and CRP levels.Results Compared with the placebo-control group,the reduction ranges of body weight,BMI,waist circumference and hip circumference at the end of the 12th week increased significantly in the treatment group(P<0.05).In the treatment group,TC,LDL-C and TG decreased significantly at the end of the 12th week compared to those before treatment(P<0.05),but HDL-C had no significant change at the end of the 12th week.At the end of the 12th week,TC,LDL-C and TG in the treatment group were lower those in the placebo-control group(P<0.05).ALT reduced significantly in the treatment group at the end of the 12th week compared with that before treatment(P<0.05).There was no significant difference in AST,Scr or BUN before and after treatment(P>0.05).CRP decreased while adiponectin increased significantly in the treatment group at the end of the 12th week compared with those before treatment(P<0.05).Compared with the placebo-control group,CRP decreased significantly and adiponectin increased significantly in treatment group at the end of the 12th week(P<0.05).Conclusions Oxytocin can reduce the body weight of obese patients,improve lipid metabolism and ameliorate obesity chronic inflammatory state.Oxytocin has no adverse effect on hepatic or renal functions.